Prediabetes

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D

Retrieved on: 
Monday, March 18, 2024
Diagnosis, Glucose, Histology, Adipose tissue, Arm, Glycated hemoglobin, Type 2 diabetes, Disease, Connective tissue, Steatosis, Insulin, Weight gain, Diabetes, CT1, Patient, Inflammation, SGLT2, Adiponectin, Table, MASH, MD, Liver injury, Insulin resistance, LEGEND, Fibrosis, HDL, Fatty liver disease, Empagliflozin, Safety, Euronext Paris, Phase, NASH, Hepatitis, Lipid metabolism, Prediabetes, Liver disease

Patients treated with lanifibranor in combination with empagliflozin maintained a stable weight throughout the 24 weeks study, addressing the moderate, metabolically healthy, weight gain that has been observed in some patients treated with lanifibranor.

Key Points: 
  • Patients treated with lanifibranor in combination with empagliflozin maintained a stable weight throughout the 24 weeks study, addressing the moderate, metabolically healthy, weight gain that has been observed in some patients treated with lanifibranor.
  • The treatment with lanifibranor 800mg/once daily alone or in combination with empagliflozin for 24 weeks was well tolerated, with no safety concerns reported.
  • The trial is double-blind for the placebo arm and lanifibranor (800mg daily) arm, and open-label for the combination of lanifibranor (800mg daily) and empagliflozin (10 mg daily) arm.
  • More details on these results are expected to be presented in upcoming scientific conferences and submitted for publication.

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 28, 2024
Oncology, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Diagnosis, De novo, PIN, Obesity, MRI, Syndrome, Metabolism, KCH, Knowledge Organization (journal), International, National Health Service, NHS, Research, Radiology, MASH, Trial of the century, International Classification of Diseases, Hepatology, World Health Organization, Data collection, Prediabetes, NDRA, Liver, Type 2 diabetes, Liver disease, Marketing, NAFLD, Endocrinology, Video game

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three months and year ended December 31, 2023 and provides a business update.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three months and year ended December 31, 2023 and provides a business update.
  • Highlights from the fourth quarter of 2023 and recent weeks include:
    Installed first TAEUS system in the UK at King’s College Hospital for clinical evaluation.
  • In the third quarter of 2023, ENDRA submitted a De Novo request for its TAEUS liver system to the FDA.
  • In the fourth quarter of 2023, the FDA issued an Additional Information (AI) request to ENDRA.

Nourish Raises $35M Series A to Expand Access to Registered Dietitians

Retrieved on: 
Wednesday, March 27, 2024
Other Health, Software, Telemedicine, Virtual Medicine, Oncology, Apps, Applications, Technology, Artificial Intelligence, Fitness & Nutrition, Health Insurance, Cardiology, Health, Diabetes, Blood pressure, Partner, BoxGroup, Growth, Y Combinator, Disease, TCV, Patient, Conditional sentence, Weight loss, Food, Thrive Capital, Index Ventures, Cancer, NPS, Insurance, Eating disorder, Adolescence, Diet, RDS, Access, Prediabetes, Medicine

Nourish , a telenutrition platform that connects people to registered dietitians covered by insurance, announced today that it has raised $35 million in Series A funding.

Key Points: 
  • Nourish , a telenutrition platform that connects people to registered dietitians covered by insurance, announced today that it has raised $35 million in Series A funding.
  • With $44M in total funding since its founding in 2021, Nourish plans to accelerate development of its digital platform for patients and providers, expand its network of registered dietitians (RDs), and deepen its strategic partnerships with insurance companies.
  • “Our goal is to create a win-win-win for patients, providers, and payers,” said Sam Perkins, co-founder, President and COO of Nourish.
  • “Nourish aims to help tens of millions of Americans by providing access to a dietitian and the incredible nutritional education, accountability, and care that they provide.

L-Nutra's Groundbreaking Study Revolutionizes Type 2 Diabetes Management Through Fasting Mimicking Nutrition Technology

Retrieved on: 
Thursday, April 4, 2024
Glycated hemoglobin, Metabolism, FMD, Type 2 diabetes, Disease, Insulin, Diabetes, Patient, Research, Fasting, Standard of care, Food, Doctor of Philosophy, Diet, Insulin resistance, Clinical trial, Type 2, Safety, Waist, BMI, Metformin, Movement, Prediabetes, Pharmaceutical industry

This randomized, controlled, assessor-blinded trial introduces a new paradigm in diabetes management, focusing on "glycemic management,'' a new metric used to measure efficacy by medication reduction.

Key Points: 
  • This randomized, controlled, assessor-blinded trial introduces a new paradigm in diabetes management, focusing on "glycemic management,'' a new metric used to measure efficacy by medication reduction.
  • Glycemic Management: FMD participants demonstrated superior glycemic management, with 53% showing improvement, compared to only 8% in the control group.
  • L-Nutra's patented and clinically backed nutrition technology food formulations are effective in supporting metabolism, cell renewal, and muscle protection by mimicking the reset and rejuvenation pathways of fasting.
  • "With the Fasting Mimicking Diet, we have successfully enhanced the natural rejuvenating power of fasting with food which has made the regression and remission of diabetes within every patient's reach.

Two National Employers Select Dario's Integrated Chronic Condition Solution to Improve Employee Health

Retrieved on: 
Tuesday, April 2, 2024
Diabetes, Prediabetes, Hypertension

NEW YORK, April 2, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new contracts to provide integrated chronic condition management solutions for two national employers beginning in the second quarter of 2024.

Key Points: 
  • NEW YORK, April 2, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new contracts to provide integrated chronic condition management solutions for two national employers beginning in the second quarter of 2024.
  • The first employer, a global private investment group, selected Dario's cardiometabolic suite to help improve outcomes for employees with cardiometabolic health conditions, including diabetes, pre-diabetes, hypertension and weight management needs, including support for individuals taking a GLP-1.
  • The second employer, a national professional services company, selected Dario's full suite of solutions to deliver personalized support for employees living with cardiometabolic health conditions and commonly co-occurring musculoskeletal and behavioral health needs.
  • "The need for an integrated approach to address the most common and chronic health needs continues to drive demand for Dario's multi-chronic solutions.

DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results

Retrieved on: 
Thursday, March 28, 2024
Nexus, DTS, Sanofi, Growth, Partnership, Diabetes, Webcast, Ratio, Research, Acquisition, Diabetes Technology Society, Prediabetes, Traction, Depreciation, GAAP, Hypertension, Total, Medicine, Marketing, Video game

NEW YORK, March 28, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today reported financial results for the fourth quarter 2023 and the full year 2023 and provided a corporate and commercial update.

Key Points: 
  • NEW YORK, March 28, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today reported financial results for the fourth quarter 2023 and the full year 2023 and provided a corporate and commercial update.
  • Gross profit as a percentage of revenues decreased to 3.7% in the fourth quarter of 2023, from 40.1% in the fourth quarter of 2022, and 17.3% in the third quarter of 2023.
  • Total operating expenses for the fourth quarter ended December 31, 2023, were $14.3 million compared with $11.7 million for the fourth quarter ended December 31, 2022, and $16.1 million for the third quarter of 2023, an increase of $2.6 million, or 22.2%, compared to the fourth quarter of 2022, and a decrease of $1.8 million, or 11.2%, compared to the third quarter of 2023.
  • Total operating expenses excluding stock-based compensation, acquisition expenses and depreciation for the fourth quarter of 2023 were $9.9 million compared to $10 million for the fourth quarter of 2022, and $10.9 million for the third quarter of 2023.

Digital Personalized Nutrition Market to Reach USD 1.57 Billion by 2029, Subscription Purchase Model to Dominates, APAC Takes Center Stage - Arizton

Retrieved on: 
Wednesday, March 27, 2024
Health, Consumer, Growth, Garmin, Data analysis, Dietary supplement, Partnership, App Store (iOS/iPadOS), Noom, Diet, GDP, Compound annual growth rate, Prediabetes, Food delivery

The subscription-based digital personalized nutrition model is well-suited for people looking for a continuous and comprehensive approach to their health and nutrition journey.

Key Points: 
  • The subscription-based digital personalized nutrition model is well-suited for people looking for a continuous and comprehensive approach to their health and nutrition journey.
  • Nevertheless, the expenses associated with nutrition programs and dietary supplements pose potential challenges to developing the digital personalized nutrition market in the region.
  • Precise estimation of market size: Accurate assessments of the digital personalized nutrition market size and its contribution and focusing on key market segments.
  • Competitive landscape analysis: A thorough examination of the market's competitive landscape is presented, including detailed information about companies operating in the digital personalized nutrition market.

Digital Personalized Nutrition Market to Reach USD 1.57 Billion by 2029, Subscription Purchase Model to Dominates, APAC Takes Center Stage - Arizton

Retrieved on: 
Wednesday, March 27, 2024
Health, Consumer, Growth, Garmin, Data analysis, Dietary supplement, Partnership, App Store (iOS/iPadOS), Noom, Diet, GDP, Compound annual growth rate, Prediabetes, Food delivery

The subscription-based digital personalized nutrition model is well-suited for people looking for a continuous and comprehensive approach to their health and nutrition journey.

Key Points: 
  • The subscription-based digital personalized nutrition model is well-suited for people looking for a continuous and comprehensive approach to their health and nutrition journey.
  • Nevertheless, the expenses associated with nutrition programs and dietary supplements pose potential challenges to developing the digital personalized nutrition market in the region.
  • Precise estimation of market size: Accurate assessments of the digital personalized nutrition market size and its contribution and focusing on key market segments.
  • Competitive landscape analysis: A thorough examination of the market's competitive landscape is presented, including detailed information about companies operating in the digital personalized nutrition market.